Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- □ X The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- □ X A statement of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- □ X The statistical test(s) used AND whether they are one- or two-sided
- □ X Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- □ X A description of all covariates tested
- □ X A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- □ X A full description of the statistical parameters including central tendency (e.g. mean), dispersion (e.g. standard deviation or variance), and sample size (n)
- □ X For all null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
- □ X Give P values as exact values wherever possible
- □ X For 3D analysis, information on the choice of priors and Markov chain Monte Carlo settings
- □ X For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- □ X Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for editors contains articles on many of the points above.

Software and code

Policy information about availability of computer code.

Data collection

The online server PEP-FOLD2 (https://bixon.rpbs.univ-paris-diderot.fr/services/PEP-FOLD2/) and AmberTools22 were used to generate the initial peptide structures. The open source code GROMACS 2018.2 (https://www.gromacs.org/) was used to perform the MD simulations and generate the data.

Data analysis

Visual Molecular Dynamics (VMD) 1.9.2 was used to visualize and analyze the MD trajectories.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data.

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third-party data, please ensure that the statement adheres to our policy.

The data generated in this study have been deposited in the DR-NTU(data) under accession code https://doi.org/10.21979/N9/BOOV1A.
Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

| Reporting on sex and gender | Not Applicable |
|-----------------------------|----------------|
| Population characteristics  | Not Applicable |
| Recruitment                 | Not Applicable |
| Ethics oversight            | Not Applicable |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- [x] Life sciences
- [ ] Behavioural & social sciences
- [ ] Ecological, evolutionary & environmental sciences

For reference COPY the document with all sections, see nature.com/documents/ireporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size  | not applicable |
|--------------|----------------|
| Data exclusions | not applicable |
| Replication  | not applicable |
| Randomization | not applicable |
| Blinding     | not applicable |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

| n/a | Involved in the study |
|-----|-----------------------|
| [x] | Antibodies            |
| [x] | Eukaryotic cell lines |
| [x] | Palaeontology and archaeology |
| [x] | Animals and other organisms |
| [x] | Clinical data         |
| [x] | Dual use research of concern |

Methods

| n/a | Involved in the study |
|-----|-----------------------|
| [x] | ChIP-seq               |
| [x] | Flow cytometry         |
| [x] | MRI-based neuroimaging |